吡咯萘啶-青蒿琥酯或双氢青蒿素-哌喹与现行一线方案重复治疗无并发症疟疾的3b/4期试验
结果显示吡咯萘啶-青蒿琥酯和双氢青蒿素-哌喹在2年疟疾发病率及无并发症疟疾的充分临床和寄生虫学应答(ACPR)方面不劣于现行一线ACT,重复治疗耐受性良好。
要点
- 吡咯萘啶-青蒿琥酯和双氢青蒿素-哌喹重复治疗疟疾的疗效不劣于一线ACT。
- 吡咯萘啶-青蒿琥酯可见轻度一过性转氨酶升高,双氢青蒿素-哌喹可见轻度QTcF延长。
核心结论
- 吡咯萘啶-青蒿琥酯和双氢青蒿素-哌喹治疗及重复治疗疟疾耐受性良好,疗效不劣于一线ACT。
- 研究支持在西非扩大这些有效治疗的可及性。
研究设计与样本
- 随机、多中心、开放标签、纵向、对照3b/4期临床试验,在布基纳法索、几内亚和马里7个三级中心开展。
- 2011年10月24日至2016年2月1日共分配4710例符合条件参与者:吡咯萘啶-青蒿琥酯1342例、阿莫地喹-青蒿琥酯1061例、双氢青蒿素-哌喹1340例、蒿甲醚-苯芴醇967例。
- 治疗为口服片剂或颗粒剂,按体重每日1次或2次、疗程3天,门诊随访至第42天。
- 研究注册于泛非临床试验注册中心(PACTR201105000286876)。
关键数值与推荐
- 主要结局为非劣效比较:意向治疗人群2年镜检确诊疟疾(含复杂与无并发症)发病率,非劣效界值20%。
- 主要结局还包括符合方案人群第28天和第42天无并发症疟疾的充分临床和寄生虫学应答,非劣效界值5%。
- 研究期间发生9例死亡,均与研究治疗无关。
- 吡咯萘啶-青蒿琥酯较对照药多见轻度一过性转氨酶升高,双氢青蒿素-哌喹较对照药多见轻度QTcF延长。
临床怎么用
- 在无并发症疟疾的初始治疗和重复治疗中,吡咯萘啶-青蒿琥酯和双氢青蒿素-哌喹可作为现有ACT的替代选择。
- 西非地区可考虑增加这两种ACT的可及性以促进ACT多样化。
- 使用吡咯萘啶-青蒿琥酯时关注转氨酶,使用双氢青蒿素-哌喹时关注QTcF。
局限性
- 研究为开放标签设计,仅寄生虫学评估人员对治疗分配设盲。
- 研究在布基纳法索、几内亚和马里的7个三级中心开展,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Artemether-lumefantrine and artesunate-amodiaquine are used as first-line artemisinin-based combination therapies (ACTs) in west Africa. Pyronaridine-artesunate and dihydroartemisinin-piperaquine are potentially useful for diversification of ACTs in this region, but further safety and efficacy data are required on malaria retreatment. METHODS: We did a randomised, multicentre, open-label, longitudinal, controlled phase 3b/4 clinical trial at seven tertiary centres in Burkina Faso, Guinea, and Mali. Eligible participants for first malaria episode and all retreatment episodes were adults and children aged 6 months and older with microscopically confirmed Plasmodium spp malaria (>0 to <200 000 parasites per μL of blood) and fever or history of fever in the previous 24 h. Individuals with severe or complicated malaria, an alanine aminotransferase concentration of more than twice the upper limit of normal, or a QTc greater than 450 ms were excluded. Using a randomisation list for each site, masked using sealed envelopes, participants were assigned to either pyronaridine-artesunate or dihydroartemisinin-piperaquine versus either artesunate-amodiaquine or artemether-lumefantrine. Block sizes were two or four if two treatments were allocated, and three or six if three treatments were allocated. Microscopists doing the parasitological assessments were masked to treatment allocation. All treatments were once-daily or twice-daily tablets or granules given orally and dosed by bodyweight over 3 days at the study centre. Patients were followed up as outpatients up to day 42, receiving clinical assessments on days 0, 1, 2, 3, 7, 14, 21, 28, 35, and 42. Two primary outcomes were compared for non-inferiority: the 2-year incidence rate of all microscopically confirmed, complicated and uncomplicated malaria episodes in patients in the intention-to-treat population (ITT; non-inferiority margin 20%); and adequate clinical and parasitological response (ACPR) in uncomplicated malaria across all episodes (unadjusted and PCR-adjusted for Plasmodium falciparum and unadjusted for other Plasmodium spp) in the per-protocol population on days 28 and 42 (non-inferiority margin 5%). Safety was assessed in all participants who received one dose of study drug. This study is registered at the Pan African Clinical Trials Registry (PACTR201105000286876). FINDINGS: Between Oct 24, 2011, and Feb 1, 2016, we assigned 4710 eligible participants to the different treatment strategies: 1342 to pyronaridine-artesunate, 967 to artemether-lumefantrine, 1061 to artesunate-amodiaquine, and 1340 to dihydroartemisinin-piperaquine. The 2-year malaria incidence rate in the ITT population was non-inferior for pyronaridine-artesunate versus artemether-lumefantrine (1·77, 95% CI 1·63-1·93 vs 1·87, 1·72-2·03; rate ratio [RR] 1·05, 95% CI 0·94-1·17); and versus artesunate-amodiaquine (1·39, 95% CI 1·22-1·59 vs 1·35, 1·18-1·54; RR 0·97, 0·87-1·07). Similarly, this endpoint was non-inferior for dihydroartemisinin-piperaquine versus artemether-lumefantrine (1·16, 95% CI 1·01-1·34 vs 1·42 1·25-1·62; RR 1·22, 95% CI 1·06-1·41) and versus artesunate-amodiaquine (1·35, 1·21-1·51 vs 1·68, 1·51-1·88; RR 1·25, 1·02-1·50). For uncomplicated P falciparum malaria, PCR-adjusted ACPR was greater than 99·5% at day 28 and greater than 98·6% at day 42 for all ACTs; unadjusted ACPR was higher for pyronaridine-artesunate versus comparators at day 28 (96·9% vs 82·3% for artemether-lumefantrine and 95·6% vs 89·0% for artesunate-amodiaquine) and for dihydroartemisinin-piperaquine versus comparators (99·5% vs 81·6% for artemether-lumefantrine and 99·0% vs 89·0% for artesunate-amodiaquine). For non-falciparum species, unadjusted ACPR was greater than 98% for all study drugs at day 28 and at day 42 was greater than 83% except for artemether-lumefantrine against Plasmodium ovale (in ten [62·5%] of 16 patients) and against Plasmodium malariae (in nine [75·0%] of 12 patients). Nine deaths occurred during the study, none of which were related to the study treatment. Mostly mild transient elevations in transaminases occurred with pyronaridine-artesunate versus comparators, and mild QTcF prolongation with dihydroartemisinin-piperaquine versus comparators. INTERPRETATION: Pyronaridine-artesunate and dihydroartemisinin-piperaquine treatment and retreatment of malaria were well tolerated with efficacy that was non-inferior to first-line ACTs. Greater access to these efficacious treatments in west Africa is justified. FUNDING: The European and Developing Countries Clinical Trial Partnership, Medicines for Malaria Venture (Geneva, Switzerland), the UK Medical Research Council, the Swedish International Development Cooperation Agency, German Ministry for Education and Research, University Claude Bernard (Lyon, France), University of Science, Techniques and Technologies of Bamako (Bamako, Mali), the Centre National de Recherche et de Formation sur le Paludisme (Burkina Faso), Institut de Recherche en Sciences de la Santé (Bobo-Dioulasso, Burkina Faso), and Centre National de Formation et de Recherche en Santé Rurale (Republic of Guinea).
引用
- Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet. 2018. PMID: 29606364. doi:10.1016/S0140-6736(18)30291-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。